Abstract Library

#4578 Dissecting the role of collagen quantitation via tissue-tethered digital analysis in small bowel neuroendocrine tumours and related mesenteric tumour deposits

Introduction: Small bowel neuroendocrine tumours (sb-NETs) and related mesenteric tumour deposits (MTDs) can present dense collagen and fibrosis. Despite well-known clinical consequences of this characteristic (bowel obstruction and ischemia), the relationship between SB-NETs and MTDs collagen deposition has been poorly evaluated.

Conference:

Presenting Author: Ali M

Authors: Ali M, Gambella A, Checchin F, Malerba D, Sambuceti V,

Keywords: neuroendocrine tumour, small intestine, collagen, fibrosis,

#4282 A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas

Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,

Keywords: NEN, NEC, NET, ACC, ADC, ADCT-701,

#4065 DAREON™-7: A Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NEC) have limited treatment options. DLL3 is highly expressed on NEC and is a promising treatment target. In an ongoing Phase I trial (NCT04429087), BI 764532, a DLL3/CD3 IgG-like T-cell engager (TcE), was tolerable with promising activity in pretreated pts with DLL3-positive (+) tumours, including NEC.

Conference:

Presenting Author: Capdevila J

Authors: Capdevila J, Vandamme T, Niccoli P, Mishima S, Kato K,

Keywords: neuroendocrine carcinoma, delta-like ligand, T-cell engager, Phase I,

#4019 Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)

Introduction: DLL3 is expressed on several cancers including epNECs. BI 764532 is a DLL3/CD3 IgG-like T-cell engager. NCT04429087 is a Phase I trial of BI 764532 in pts with locally advanced/metastatic DLL3+ small-cell lung cancer, epNEC or large-cell neuroendocrine lung carcinoma. Here we focus on pts with epNEC.

Conference:

Presenting Author: Capdevila J

Authors: Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D,

Keywords: DLL3, NEC, T-cell engager,

#3161 Phase 1 trial of PARP inhibitor combined with 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastatic neuroendocrine tumor - PARLuNET

Introduction: 177Lu-DOTA-Octreotate (177Lu-DOTATATE) is an effective treatment for patients with grade 1 and 2 NET. However, strategies are required to optimize treatment efficacy and outcomes. Combining a DNA-repair modifying agent could further enhance radiation efficacy. Pre-clinical data supports that a PARP inhibitor (PARPi) combined with PRRT significantly enhances NET cell death and animal survival compared to 177Lu-DOTATATE alone. This combination strategy aims to enhance radiation efficacy from PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Hatzimihalis A, Hogg A, Bressel M, Hicks R,

Keywords: PRRT, PARP inhibitor, combination therapy, NET, pancreatic, phase 1,